Decentralized and adaptive trial designs move from pilot to default in biotech development plans
Dr. Dereck Mush, MD, MBA
Paradigm
Integrated clinical trial platform that simplifies access for patients and providers.
What they do
Paradigm offers an end-to-end clinical trial platform designed to integrate trials into routine clinical care. The software connects healthcare providers and pharmaceutical sponsors, reducing the administrative burden on sites and making clinical research accessible to a more diverse patient population.
The record
- Vertical
- Clinical Trials
- Sub-segment
- Trial administration
- Product type
- Platform software
- Stage
- Series A
- Headquarters
- New York, United States
- Region
- North America
- Founded
- 2022
- Total funding
- $203M raised
Notable investors: Arch Venture Partners, General Catalyst, F-Prime Capital.
Also in Clinical Trials
Related on The Signal
Dr. Dereck Mush, MD, MBA
Oracle and AstraZeneca: Bringing Clinical Trials Closer to Care
Dr. Dereck Mush, MD, MBA
Decentralized Clinical Trials Promised Faster Recruitment. The Evidence on Actual Performance Is In.
Dr. Dereck Mush, MD, MBA
The Non-Covalent Oncology Paradigm: Jaypirca's Frontline Infiltration and the BTK Landscape
Dr. Dereck Mush, MD, MBA